Literature DB >> 10912224

APOE epsilon 4 influences the manifestation of Alzheimer's disease in adults with Down's syndrome.

S Deb1, J Braganza, N Norton, H Williams, P G Kehoe, J Williams, M J Owen.   

Abstract

BACKGROUND: Recent studies of the relationship between the apolipoprotein E (APOE) gene and Alzheimer's disease in adults with Down's syndrome have revealed inconsistent results. AIMS: To assess the role of the APOE gene in the manifestation of Alzheimer's disease in adults with Down's syndrome.
METHOD: We studied the APOE genotypes of 24 adults with dementia and 33 non-demented adults with Down's syndrome over 35 years of age, and an additional group of 164 non-learning disabled adults. We also carried out a meta-analysis of all previously published studies of association between APOE and Down's syndrome, incorporating the current data.
RESULTS: We observed a non-significant excess of APOE epsilon 4 and a reduction of epsilon 2 in adults with dementia compared with non-demented adults with Down's syndrome in our sample. However, meta-analysis showed a significantly higher frequency of epsilon 4 in adults with dementia compared with non-demented adults with Down's syndrome (odds ratio = 2.02, 95% CI 1.33-3.07, P = 0.001), but no significant reduction in the frequency of epsilon 2.
CONCLUSIONS: The APOE epsilon 4 allele acts as a risk factor for the age-specific manifestation of Alzheimer's disease in people with Down's syndrome.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10912224     DOI: 10.1192/bjp.176.5.468

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  13 in total

1.  ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis.

Authors:  Anne M Fagan; Erin Christopher; Jennie W Taylor; Maia Parsadanian; Michael Spinner; Melanie Watson; John D Fryer; Suzanne Wahrle; Kelly R Bales; Steven M Paul; David M Holtzman
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

2.  Alzheimer's Disease in Adults with Down Syndrome.

Authors:  Warren B Zigman; Darlynne A Devenny; Sharon J Krinsky-McHale; Edmund C Jenkins; Tiina K Urv; Jerzy Wegiel; Nicole Schupf; Wayne Silverman
Journal:  Int Rev Res Ment Retard       Date:  2008-01-01

Review 3.  Dysregulation of neurotrophin signaling in the pathogenesis of Alzheimer disease and of Alzheimer disease in Down syndrome.

Authors:  Xu-Qiao Chen; Mariko Sawa; William C Mobley
Journal:  Free Radic Biol Med       Date:  2017-10-12       Impact factor: 7.376

4.  Is Apolipoprotein E4 an Important Risk Factor for Dementia in Persons with Down Syndrome?

Authors:  Troy T Rohn; Katie L McCarty; Julia E Love; Elizabeth Head
Journal:  J Parkinsons Dis Alzheimers Dis       Date:  2014-12-08

Review 5.  Rodent Modeling of Alzheimer's Disease in Down Syndrome: In vivo and ex vivo Approaches.

Authors:  Clíona Farrell; Paige Mumford; Frances K Wiseman
Journal:  Front Neurosci       Date:  2022-06-07       Impact factor: 5.152

Review 6.  Cell models for Down syndrome-Alzheimer's disease research.

Authors:  Yixing Wu; Nicole R West; Anita Bhattacharyya; Frances K Wiseman
Journal:  Neuronal Signal       Date:  2022-04-08

7.  Significant effect of APOE epsilon 4 genotype on the risk of dementia in Alzheimer's disease and mortality in persons with Down syndrome.

Authors:  V P Prasher; S G Sajith; S D Rees; A Patel; S Tewari; N Schupf; W B Zigman
Journal:  Int J Geriatr Psychiatry       Date:  2008-11       Impact factor: 3.485

Review 8.  A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome.

Authors:  Frances K Wiseman; Tamara Al-Janabi; John Hardy; Annette Karmiloff-Smith; Dean Nizetic; Victor L J Tybulewicz; Elizabeth M C Fisher; André Strydom
Journal:  Nat Rev Neurosci       Date:  2015-08-05       Impact factor: 34.870

9.  The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome.

Authors:  Michael S Rafii; Hannah Wishnek; James B Brewer; Michael C Donohue; Seth Ness; William C Mobley; Paul S Aisen; Robert A Rissman
Journal:  Front Behav Neurosci       Date:  2015-09-14       Impact factor: 3.558

10.  Genetic variants conferring susceptibility to Alzheimer's disease in the general population; do they also predispose to dementia in Down's syndrome.

Authors:  Ashok Patel; Simon D Rees; M Ann Kelly; Stephen C Bain; Anthony H Barnett; Anisha Prasher; Humaria Arshad; Vee P Prasher
Journal:  BMC Res Notes       Date:  2014-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.